Hydrolases

Global Industrial Enzymes Market (2020 to 2027) - Featuring BASF, Novozymes and DSM Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Engineering, Chemicals, Plastics, Manufacturing, Proteins, Chemistry, Enzymes, Physical sciences, Catalysis, Hydrolases, Lipase, Industrial enzymes, Cellulase, Enzyme, Biotechnology, Cross-linked enzyme aggregate

Further, the market for industrial enzymes is continuously rising, owing to the growing need for sustainable solutions.

Key Points: 
  • Further, the market for industrial enzymes is continuously rising, owing to the growing need for sustainable solutions.
  • Advancement in biotechnology, especially in protein engineering, has also brought in new probiotic products, driving the industrial enzymes market to the next level.
  • Carbohydrases, Amylases, Cellulases, Proteases and Lipases are major variants existing in the global Enzymes Market.
  • Additionally, expanding investment in the food and beverage and pharmaceutical industry is anticipated to stimulate the overall industrial enzymes market.

MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal

Retrieved on: 
Monday, June 7, 2021
Hydrolases, Health, Clinical medicine, Bromelain, Bromeliaceae, Basal-cell carcinoma, Anatomy, Carcinoma

The paper, entitled Basal Cell Carcinoma Destruction by a Concentrate of Proteolytic Enzymes Enriched in Bromelain: A Preliminary Report (opendermatologyjournal.com ) , details case series experience using a concentrate of proteolytic enzymes enriched in bromelain for the destruction of six BCC tumors.

Key Points: 
  • The paper, entitled Basal Cell Carcinoma Destruction by a Concentrate of Proteolytic Enzymes Enriched in Bromelain: A Preliminary Report (opendermatologyjournal.com ) , details case series experience using a concentrate of proteolytic enzymes enriched in bromelain for the destruction of six BCC tumors.
  • The findings provide a preliminary proof-of-concept that a concentrate of proteolytic enzymes enriched in bromelain may be a safe and effective destructive treatment for basal cell carcinomas.
  • "We are very excited to have our case series data published in a peer reviewed paper," said Prof. Lior Rosenberg, Chief Medical Technology Officer of MediWound.
  • MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration.

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - 2021 Drugs in Development Report - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, Pharmaceutical, Enzymes, Lysosomal storage diseases, Maltase, Acid alpha-glucosidase, Alpha-glucosidase, Hydrolases, Carbohydrates, Lysosome, Glucosidases, Glucocerebrosidase, GAA, Glucan 1,4-a-glucosidase

The "Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) pipeline Target constitutes close to 19 molecules.
  • The report outlays comprehensive information on the Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics development with respective active and dormant or discontinued projects.

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

Retrieved on: 
Thursday, April 1, 2021
Enzymes, Branches of biology, Catalysts, GLB1, Galactosides, Hydrolases, Lysosomal storage disease, Rare diseases, Beta-galactosidase, Lysosome, GM1 gangliosidoses

GM1, a rare monogenic lysosomal storage disease, is caused by mutations in the GLB1 gene, which encodes the lysosomal enzyme beta-galactosidase (-gal).

Key Points: 
  • GM1, a rare monogenic lysosomal storage disease, is caused by mutations in the GLB1 gene, which encodes the lysosomal enzyme beta-galactosidase (-gal).
  • We are extremely grateful to the families and patients for volunteering to support the effort to bring the PBGM01 gene therapy into clinical studies.
  • The clinical program will enroll a total of four cohorts of two patients each, with separate dose-escalation cohorts for late infantile GM1 and early infantile GM1.
  • As part of the global Imagine-1 study for PBGM01, Passage Bio plans to open 10 clinical study sites around the world, many of which are considered GM1 Centers of Excellence.

MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

Retrieved on: 
Tuesday, February 16, 2021
Life sciences, Health sciences, Biology, Necrosis, Hydrolases, Bromelain, Eschar, Biopharmaceutical

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.

Key Points: 
  • To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
  • An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
  • MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds.
  • MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.

MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Wednesday, February 10, 2021
Medicine, Clinical medicine, Health sciences, Necrosis, Hydrolases, Debridement, Eschar, Bromelain, Biopharmaceutical, Wound

A live webcast of the fireside chat will be available on Events page of the Investors section of the company's website: www.mediwound.com .

Key Points: 
  • A live webcast of the fireside chat will be available on Events page of the Investors section of the company's website: www.mediwound.com .
  • MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.
  • MediWounds second innovative product, EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.
  • In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.

Pursuit of Novel Plant-based Enzymes for Skincare Industry Broaden Horizon for Companies in Bromelain Market: TMR

Retrieved on: 
Wednesday, January 13, 2021
Dietary Supplements, Bromelain, Bromeliaceae, Hydrolases

Skincare product manufacturers world over have been exhibiting interest in bromelain market to expand their portfolios of products containing plant-based ingredients.

Key Points: 
  • Skincare product manufacturers world over have been exhibiting interest in bromelain market to expand their portfolios of products containing plant-based ingredients.
  • This opens the bromelain market to some of the most attractive opportunities among companies in the pharmaceutical and the dietary supplements industries.
  • The focus on clean labelling ingredients among food brands is another area of interest for players in the bromelain market.
  • Expanding opportunities in dietary food supplements industry will also expand the horizon of stakeholders in the bromelain market.

Pursuit of Novel Plant-based Enzymes for Skincare Industry Broaden Horizon for Companies in Bromelain Market: TMR

Retrieved on: 
Wednesday, January 13, 2021
Dietary Supplements, Bromelain, Bromeliaceae, Hydrolases

Skincare product manufacturers world over have been exhibiting interest in bromelain market to expand their portfolios of products containing plant-based ingredients.

Key Points: 
  • Skincare product manufacturers world over have been exhibiting interest in bromelain market to expand their portfolios of products containing plant-based ingredients.
  • This opens the bromelain market to some of the most attractive opportunities among companies in the pharmaceutical and the dietary supplements industries.
  • The focus on clean labelling ingredients among food brands is another area of interest for players in the bromelain market.
  • Expanding opportunities in dietary food supplements industry will also expand the horizon of stakeholders in the bromelain market.

Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent

Retrieved on: 
Monday, December 21, 2020
Clinical medicine, Medicine, Hydrolases, Health, Debridement, Dietary Supplements, Bromelain

The study concluded that EscharEx treatment was more effective than the commercially available collagenase agent in removing eschars in this model.

Key Points: 
  • The study concluded that EscharEx treatment was more effective than the commercially available collagenase agent in removing eschars in this model.
  • We are encouraged by the robust results of this in-vivo study comparing EscharEx to the commercially available enzymatic debriding agent, said Sharon Malka, Chief Executive Officer of MediWound.
  • Given the superior efficacy of EscharEx versus the comparator enzymatic debridement agent demonstrated in this study, as well as the positive safety and efficacy results generated in our previous phase 2 study, we believe EscharEx has the potential to become a game-changer in a sizeable market.
  • The primary objective of the study was to compare the debridement efficacy of various concentrations of EscharEx, a novel bromelain-based enzymatic agent (second generation EscharEx formulation), with a commercially available collagenase debridement agent.

MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020

Retrieved on: 
Monday, November 2, 2020
Medicine, Branches of biology, Clinical medicine, Necrosis, Hydrolases, Debridement, Eschar, Bromelain, Proteolysis

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.

Key Points: 
  • To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
  • An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
  • MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.
  • MediWounds second innovative product, EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.